{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:40:16Z","timestamp":1790170816559,"version":"4.1.0"},"reference-count":137,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ejso.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology (EJSO)"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejso.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,27]],"date-time":"2016-10-27T21:19:10Z","timestamp":1477603150000},"page":"544-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":93,"title":["Diagnosis and treatment of in-transit melanoma metastases"],"prefix":"10.1016","volume":"43","author":[{"given":"A.","family":"Testori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ribero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"36","key":"10.1016\/j.ejso.2016.10.005_bib1","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejso.2016.10.005_bib2","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1245\/s10434-007-9717-9","article-title":"Prognosis and determinants of outcome following loco-regional or distant recurrence in patients with cutaneous melanoma","volume":"15","author":"Francken","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib3","first-page":"294","article-title":"Surgical management of melanoma: an EORTC Melanoma Group Survey","volume":"7","author":"Testori","year":"2013","journal-title":"Ecancermedicalscience"},{"issue":"Suppl. 1","key":"10.1016\/j.ejso.2016.10.005_bib4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000348873","article-title":"Surgical treatment of melanoma: a Survey Of Italian Hospitals","volume":"226","author":"Testori","year":"2013","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.ejso.2016.10.005_bib5","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1529-8019.2012.01486.x","article-title":"Alternative for the treatment of local advanced disease: electrochemotherapy, limb pefusion, limb infusion, intralesional Il2. What is the role?","volume":"25","author":"Testori","year":"2012","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejso.2016.10.005_bib6","first-page":"391","article-title":"Local and intralesional therapy of in-transit melanoma metastases","volume":"104","author":"Testori","year":"2011","journal-title":"J.\u00a0A JCO"},{"key":"10.1016\/j.ejso.2016.10.005_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/jso.2930520206","article-title":"Major amputation for advanced melanoma: an epidemiological study","volume":"52","author":"Ebskov","year":"1993","journal-title":"J\u00a0Surg Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s10103-008-0580-0","article-title":"Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases","volume":"24","author":"Kandamany","year":"2009","journal-title":"Lasers Med Sci"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib9","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/00000658-195810000-00009","article-title":"Chemotherapy of cancer: regional perfusion utilizing an extracorporeal circuit","volume":"148","author":"Creech","year":"1958","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib10","first-page":"157","article-title":"Regional perfusion treatment with melphalan for melanoma in a limb: an evaluation of drug kinetics","volume":"14","author":"Benckhuijsen","year":"1988","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2016.10.005_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0277-5379(82)90235-8","article-title":"Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactions","volume":"18","author":"Wieberdink","year":"1982","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/BF01655728","article-title":"Optimization of isolated hyperthermic limb perfusion","volume":"17","author":"Omlor","year":"1993","journal-title":"World J Surg"},{"issue":"9","key":"10.1016\/j.ejso.2016.10.005_bib13","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/1097-0142(196709)20:9<1351::AID-CNCR2820200902>3.0.CO;2-#","article-title":"Selective heat sensitivity of cancer cells. Biochemical and clinical studies","volume":"20","author":"Cavaliere","year":"1967","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/00008390-199412000-00004","article-title":"Melphalan uptake, hyperthermic synergism and drug resistance in a human cell culture model for the isolated limb perfusion of melanoma","volume":"4","author":"Clark","year":"1994","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/(SICI)1098-2388(199804\/05)14:3<215::AID-SSU5>3.0.CO;2-B","article-title":"The application of hyperthermia in regional chemotherapy","volume":"14","author":"Di Filippo","year":"1998","journal-title":"Semin Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib16","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1200\/JCO.2009.23.7511","article-title":"Analysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parameters","volume":"28","author":"Alexander","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/archsurg.1995.01430010045009","article-title":"Long-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactions","volume":"130","author":"Vrouenraets","year":"1995","journal-title":"Arch Surg"},{"issue":"10","key":"10.1016\/j.ejso.2016.10.005_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1002\/bjs.1800831004","article-title":"Thirty-five years of isolated limb perfusion for melanoma: indications and results","volume":"83","author":"Vrouenraets","year":"1996","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib19","first-page":"347","article-title":"Prognostic factors influencing tumor response, loco-regional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion","volume":"23","author":"Di Filippo","year":"2009","journal-title":"In\u00a0Vivo"},{"issue":"7","key":"10.1016\/j.ejso.2016.10.005_bib20","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S1470-2045(03)01141-0","article-title":"Current uses of isolated limb perfusion in the clinic and a model system for new strategies","volume":"4","author":"Eggermont","year":"2003","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejso.2016.10.005_bib21","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1200\/JCO.1991.9.12.2091","article-title":"Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group","volume":"9","author":"Hafstrom","year":"1991","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2016.10.005_bib22","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archsurg.140.11.1115","article-title":"Predictors of outcome after hyperthermic isolated limb perfusion: role of tumor response","volume":"140","author":"Aloia","year":"2005","journal-title":"Arch Surg"},{"issue":"11","key":"10.1016\/j.ejso.2016.10.005_bib23","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1001\/archsurg.139.11.1237","article-title":"Isolated limb perfusion for unresectable melanoma of the extremities","volume":"139","author":"Noorda","year":"2004","journal-title":"Arch Surg"},{"issue":"9","key":"10.1016\/j.ejso.2016.10.005_bib24","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.ejso.2005.07.003","article-title":"TNF dose reduction in isolated limb perfusion","volume":"31","author":"Grunhagen","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib25","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1245\/s10434-006-9040-x","article-title":"Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma","volume":"14","author":"Hayes","year":"2007","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/BF02071525","article-title":"Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs","volume":"16","author":"Thompson","year":"1992","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2016.10.005_bib27","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1097\/01.sla.0000146147.89667.ed","article-title":"One hundred consecutive isolated limb perfusions with TNF-alpha and melphalan in melanoma patients with multiple in-transit metastases","volume":"240","author":"Gr\u00fcnhagen","year":"2004","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1200\/JCO.1992.10.1.52","article-title":"High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma","volume":"10","author":"Lienard","year":"1992","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2016.10.005_bib29","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/1097-0142(19930515)71:10<2990::AID-CNCR2820711017>3.0.CO;2-6","article-title":"A\u00a0retrospective comparative study evaluating the results of a single-perfusion versus double-perfusion schedule with melphalan in patients with recurrent melanoma of the lower limb","volume":"71","author":"Klaase","year":"1993","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.ejso.2016.10.005_bib30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00008390-199910000-00009","article-title":"Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study","volume":"9","author":"Lienard","year":"1999","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib31","first-page":"39","article-title":"Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan","volume":"115","author":"Klaase","year":"1994","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ejso.2016.10.005_bib32","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1054\/bjoc.1999.1032","article-title":"Tumour necrosis factor alpha increases melphalan concentration in tumour tissue after isolated limb perfusion","volume":"82","author":"de Wilt","year":"2000","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib33","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1245\/ASO.2004.03.019","article-title":"Hyperthermic isolated limb perfusion with low-dose tumor necrosis factor-alpha and melphalan for bulky in-transit melanoma metastases","volume":"11","author":"Rossi","year":"2004","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2016.10.005_bib34","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1200\/JCO.2006.09.8459","article-title":"Hyperthermic isolated limb perfusion with tumor necrosis factor is a useful therapy for advanced melanoma of the limbs","volume":"25","author":"Lejeune","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2016.10.005_bib35","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1245\/s10434-010-1104-2","article-title":"Long-term results of melphalan-based isolated limb perfusion with or without low-dose TNF for in-transit melanoma metastases","volume":"17","author":"Rossi","year":"2010","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/s10434-000-0268-6","article-title":"Systemic toxicity and cytokine\/acute phase protein levels in patients after isolated limb perfusion with tumor necrosis factor-alpha complicated by high leakage","volume":"7","author":"Stam","year":"2000","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib37","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1245\/ASO.2003.03.076","article-title":"Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors","volume":"10","author":"van Etten","year":"2003","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib38","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1053\/ejso.2001.1124","article-title":"Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone","volume":"27","author":"Vrouenraets","year":"2001","journal-title":"Eur J Surg Oncol"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib39","first-page":"1077","article-title":"Hyperthermic isolated limb perfusion for recurrent melanomas and soft tissue sarcomas: feasibility and reproducibility in a multi-institutional Hellenic collaborative study","volume":"23","author":"Lasithiotakis","year":"2010","journal-title":"Oncol Rep"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib40","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1200\/JCO.1996.14.2.479","article-title":"Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study","volume":"14","author":"Fraker","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.ejso.2016.10.005_bib41","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.1996.14.10.2653","article-title":"Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial","volume":"14","author":"Eggermont","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib42","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/00000658-199612000-00011","article-title":"Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience","volume":"224","author":"Eggermont","year":"1996","journal-title":"Ann Surg"},{"issue":"25","key":"10.1016\/j.ejso.2016.10.005_bib43","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1200\/JCO.2005.05.5152","article-title":"Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020","volume":"24","author":"Cornett","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejso.2016.10.005_bib44","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1002\/bjs.1800800918","article-title":"Systemic leakage during isolated limb perfusion for melanoma","volume":"80","author":"Klaase","year":"1993","journal-title":"Br J Surg"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib45","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/jso.23552","article-title":"Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?","volume":"109","author":"Hoekstra","year":"2014","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib46","first-page":"188","article-title":"Isolated limb infusion with melphalan for recurrent limb melanoma: a simple alternative to isolated limb perfusion","volume":"7","author":"Thompson","year":"1994","journal-title":"Reg Cancer Treat"},{"key":"10.1016\/j.ejso.2016.10.005_bib47","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/1097-0142(19820301)49:5<850::AID-CNCR2820490505>3.0.CO;2-2","article-title":"Tourniquet infusion versus hyperthermic perfusion","volume":"49","author":"Karakousis","year":"1982","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib48","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00008390-200108000-00014","article-title":"Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy","volume":"11","author":"Roberts","year":"2001","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejso.2016.10.005_bib49","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1245\/s10434-008-9954-6","article-title":"Outcomes of isolated limb infusion for melanoma. A 14-year experience","volume":"15","author":"Kroon","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib50","first-page":"508","article-title":"Isolated limb infusion for melanoma and sarcoma. A good alternative for isolated limb perfusion with cytotoxic drugs)","volume":"153","author":"Kroon","year":"2009","journal-title":"Ned Tijdschr Geneesk"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib51","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1245\/s10434-015-4969-2","article-title":"Australian multicenter study of isolated limb infusion for melanoma","volume":"23","author":"Kroon","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib52","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1245\/s10434-008-0045-5","article-title":"Outcomes of the use of isolated limb infusion for soft tissue sarcoma of the extremity","volume":"15","author":"Moncrieff","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib53","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jamcollsurg.2008.12.019","article-title":"A\u00a0multi-institutional experience of isolated limb infusion: defining response and toxicity in the US","volume":"208","author":"Beasley","year":"2009","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.ejso.2016.10.005_bib54","first-page":"189","article-title":"Isolated limb infusion for melanoma: a simple alternative to isolated limb perfusion","volume":"44","author":"Mian","year":"2001","journal-title":"Can J Surg"},{"key":"10.1016\/j.ejso.2016.10.005_bib55","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1245\/s10434-006-9138-1","article-title":"Preoperative isolated limb infusion of Doxorubicin and external irradiation for limb-threatening soft tissue sarcomas","volume":"14","author":"Hegazy","year":"2007","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib56","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.rlu.0000242602.56590.c5","article-title":"FDG PET\/CT demonstrates the effectiveness of isolated limb infusion for malignant melanoma","volume":"31","author":"Ryan","year":"2006","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.ejso.2016.10.005_bib57","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1245\/s10434-008-9988-9","article-title":"Isolated limb infusion for in-transit malignant melanoma of the extremity: a well tolerated but less effective alternative to hyperthermic isolated limb perfusion","volume":"15","author":"Beasley","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib58","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1245\/aso.2002.9.2.127","article-title":"Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma","volume":"9","author":"Lindn\u00e9r","year":"2002","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib59","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1245\/s10434-009-0717-9","article-title":"Isolated limb infusion for malignant melanoma: predictors of response and outcome","volume":"16","author":"Barbour","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.ejso.2016.10.005_bib60","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1245\/s10434-011-1646-y","article-title":"Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution","volume":"18","author":"Huismans","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib61","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1245\/ASO.2006.05.003","article-title":"A\u00a0phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity","volume":"13","author":"Brady","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib62","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1245\/s10434-009-0323-x","article-title":"Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients","volume":"16","author":"Kroon","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib63","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1097\/SLA.0b013e3181a77ce5","article-title":"Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced loco-regional melanoma","volume":"246","author":"Kroon","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2016.10.005_bib64","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1245\/s10434-009-0326-7","article-title":"Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma","volume":"16","author":"Kroon","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib65","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1002\/cncr.24220","article-title":"Efficacy of repeat isolated limb infusion with melphalan and actinomycin-D for recurrent melanoma","volume":"115","author":"Kroon","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib66","doi-asserted-by":"crossref","first-page":"4766","DOI":"10.1002\/cncr.24509","article-title":"A\u00a0phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma","volume":"115","author":"Beasley","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib67","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1080\/02656730701827573","article-title":"Future directions in regional treatment strategies for melanoma and sarcoma","volume":"24","author":"Beasley","year":"2008","journal-title":"Int J Hyperth"},{"issue":"7","key":"10.1016\/j.ejso.2016.10.005_bib68","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1245\/s10434-016-5150-2","article-title":"Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma","volume":"23","author":"Dossett","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib69","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1245\/s10434-008-0288-1","article-title":"Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?","volume":"16","author":"Beasley","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib70","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/0360-3016(91)90106-E","article-title":"Effects of oxygenation and pH on tumor cell response to alkylating chemotherapy","volume":"20","author":"Siemann","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"10.1016\/j.ejso.2016.10.005_bib71","first-page":"1","article-title":"Novel dermatologic uses of the immune response modifier imiquimod 5% cream","volume":"7","author":"Berman","year":"2002","journal-title":"Skin Ther Lett"},{"key":"10.1016\/j.ejso.2016.10.005_bib72","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1600-0560.2009.01290.x","article-title":"Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis","volume":"37","author":"Turza","year":"2010","journal-title":"J\u00a0Cutan Pathol"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib73","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/jso.23506","article-title":"Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma","volume":"109","author":"Damian","year":"2014","journal-title":"JSO"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1365-2133.2006.07664.x","article-title":"Phase I\/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma","volume":"156","author":"Green","year":"2007","journal-title":"Br J Dermat"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib75","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1002\/1097-0142(197806)41:6<2456::AID-CNCR2820410654>3.0.CO;2-B","article-title":"Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene","volume":"41","author":"Cohen","year":"1978","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib76","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00432-006-0182-9","article-title":"Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group","volume":"133","author":"Terheyden","year":"2007","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib77","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/CCO.0000000000000158","article-title":"Intralesional therapy for advanced melanoma: promise and limitation","volume":"27","author":"Agarwala","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib78","first-page":"158","article-title":"Immunological factors which influence response to immunotherapy in malignant melanoma","volume":"68","author":"Morton","year":"1970","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib79","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0025-7125(16)31889-2","article-title":"Intralesional immunotherapy of melanoma with BCG","volume":"60","author":"Rosenberg","year":"1976","journal-title":"Med Clin North Am"},{"issue":"4","key":"10.1016\/j.ejso.2016.10.005_bib80","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1002\/1097-0142(197510)36:4<1305::AID-CNCR2820360417>3.0.CO;2-#","article-title":"Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases","volume":"36","author":"Mastrangelo","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib81","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1056\/NEJM197310182891603","article-title":"Complications of BCG immunotherapy in patients with cancer","volume":"289","author":"Sparks","year":"1973","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib82","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1002\/1097-0142(19880315)61:6<1071::AID-CNCR2820610603>3.0.CO;2-T","article-title":"Intralesional interferon-alpha therapy in advanced malignant melanoma","volume":"61","author":"Von Wussow","year":"1988","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.ejso.2016.10.005_bib83","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1038\/sj.bjc.6601320","article-title":"Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases","volume":"89","author":"Radny","year":"2003","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.ejso.2016.10.005_bib84","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s00262-008-0455-z","article-title":"Local therapy of cancer with free IL-2","volume":"57","author":"Den Otter","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejso.2016.10.005_bib85","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00000441-189609000-00001","article-title":"The therapeutic value of the mixed toxins of the streptococcus of erysipelas and the bacillus prodigiousus","volume":"112","author":"Coley","year":"1896","journal-title":"Am J Med Sci"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib86","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1468-3083.2001.00254.x","article-title":"Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients","volume":"15","author":"Ridolfi","year":"2001","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib87","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/00008390-199606000-00008","article-title":"Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF","volume":"6","author":"Si","year":"1996","journal-title":"Melanoma Res"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib88","first-page":"16","article-title":"Intralesional therapy of melanoma metastases with recombinant interferon-beta","volume":"43","author":"Fierlbeck","year":"1992","journal-title":"Hautarzt"},{"key":"10.1016\/j.ejso.2016.10.005_bib89","article-title":"Preliminary results of a phase I trial of intralesional injection of CPG 7909 in patients with basal cell carcinoma or melanoma","volume":"21","author":"Trefzer","year":"2002","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib90","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1200\/JCO.2006.07.9129","article-title":"Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma","volume":"24","author":"Pashenkov","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib91","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1245\/s10434-009-0809-6","article-title":"Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma","volume":"17","author":"Kaufman","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib92","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable responce rate in patients with advanced melanoma","volume":"33\u201325","author":"Andtbacka","year":"2015","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib93","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1097\/CMR.0b013e3283390711","article-title":"A\u00a0phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma","volume":"20","author":"Bedikian","year":"2010","journal-title":"Melanoma Res"},{"issue":"23","key":"10.1016\/j.ejso.2016.10.005_bib94","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-Related Response Criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejso.2016.10.005_bib95","series-title":"A\u00a0phase I study with LTX-315, an immunogenic cell death inducer, in patients with transdermally accessible tumors","author":"Brunsvig","year":"2014"},{"key":"10.1016\/j.ejso.2016.10.005_bib96","article-title":"Intratumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces CD8 effector cells and regression in some injected tumours","author":"Spicer","year":"2015","journal-title":"ECC"},{"issue":"33","key":"10.1016\/j.ejso.2016.10.005_bib97","doi-asserted-by":"crossref","first-page":"34910","DOI":"10.18632\/oncotarget.5308","article-title":"The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells","volume":"6","author":"Eike","year":"2015","journal-title":"Oncotarget"},{"issue":"31","key":"10.1016\/j.ejso.2016.10.005_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/OTT.S95887","article-title":"The oncolytic peptide LTX-315 kills cancer cells through Bax\/Bak-regulated mitochondrial membrane permeabilization","volume":"6","author":"Zhou","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib99","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/cdd.2016.35","article-title":"The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpointBlockade","volume":"23","author":"Yamazaki","year":"2016","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.ejso.2016.10.005_bib100","doi-asserted-by":"crossref","first-page":"e68561","DOI":"10.1371\/journal.pone.0068561","article-title":"Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer","volume":"8","author":"Toomey","year":"2013","journal-title":"PLoS One"},{"issue":"5s","key":"10.1016\/j.ejso.2016.10.005_bib101","article-title":"Assessment of immune and clinical efficacy after intralesional PV-10 in injected and uninjected metastatic melanoma lesions","volume":"32","author":"Sarnaik","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib102","series-title":"Society for Immunotherapy of Cancer (SITC) Annual Meeting","article-title":"Generation of an antitumor response and immunity using a small molecule drug (PV-10)","author":"Dees","year":"2012"},{"key":"10.1016\/j.ejso.2016.10.005_bib103","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/189584a0","article-title":"Distribution and fate of rose bengal","volume":"189","author":"Bocci","year":"1961","journal-title":"Nature"},{"key":"10.1016\/j.ejso.2016.10.005_bib104","first-page":"7","article-title":"On the distribution and kinetics of injected I131 rose bengal. An experimental study with special reference to the evaluation of liver function","volume":"S354","author":"Meurman","year":"1960","journal-title":"Acta Med Scand"},{"key":"10.1016\/j.ejso.2016.10.005_bib105","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1245\/s10434-014-4169-5","article-title":"Phase 2 study of intralesional PV-10 in refractory metastatic melanoma","volume":"22","author":"Thompson","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib106","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/CMR.0b013e328331caa2","article-title":"A\u00a0novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy","volume":"20","author":"Foote","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ejso.2016.10.005_bib107","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.e21072","article-title":"A\u00a0phase 2 study of intralesional PV-10 followed by radiotherapy for localized in transit or recurrent metastatic melanoma","volume":"34","author":"Foote","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib108","doi-asserted-by":"crossref","first-page":"37893","DOI":"10.18632\/oncotarget.9247","article-title":"Intralesional rose bengal in melanoma elicits tumor immunity via activation of dendritic cells by the release of high mobility group box 1","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejso.2016.10.005_bib109","article-title":"T\u00a0cell mediated immunity after combination therapy with intralesional PV-10 and co-inhibitory blockade in a melanoma model","author":"Weber","year":"2016","journal-title":"AACR"},{"key":"10.1016\/j.ejso.2016.10.005_bib110","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1038\/sj.bjc.6600959","article-title":"In\u00a0vivo evolution of tumour cells after the generation of double-strand DNA breaks","volume":"88","author":"Mekid","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib111","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejcsup.2006.08.005","article-title":"Bases and rationale of the electrochemotherapy","volume":"4","author":"Mir","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejso.2016.10.005_bib112","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/02656730701832334","article-title":"Electrochemotherapy: an emerging cancer treatment","volume":"24","author":"Sadadcharam","year":"2008","journal-title":"Int J Hyperth"},{"key":"10.1016\/j.ejso.2016.10.005_bib113","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.sla.0000250419.36053.33","article-title":"Electrochemotherapy: aspects of preclinical development and early clinical experience","volume":"245","author":"Larkin","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2016.10.005_bib114","first-page":"229","article-title":"Electrochemotherapy with bleomycin. The first clinical experience in malignant melanoma patients","volume":"29","author":"Rudolf","year":"1995","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib115","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1001\/archderm.1996.03890350095015","article-title":"Bleomycin-mediated electrochemotherapy of metastatic melanoma","volume":"132","author":"Glass","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ejso.2016.10.005_bib116","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/(SICI)1097-0142(19980701)83:1<148::AID-CNCR20>3.0.CO;2-W","article-title":"Treatment of cutaneous and subcutaneous tumors with electrochemotherapy using intralesional bleomycin","volume":"83","author":"Heller","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib117","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1038\/bjc.1998.388","article-title":"Effective treatment of cutaneous and subcutaneous malignant tumours by electrochemotherapy","volume":"77","author":"Mir","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejso.2016.10.005_bib118","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1245\/s10434-008-0204-8","article-title":"Bleomycin-based electrochemotherapy: clinical outcome from a single institution's experience with 52 patients","volume":"16","author":"Campana","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"10.1016\/j.ejso.2016.10.005_bib119","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1245\/s10434-008-9976-0","article-title":"Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases","volume":"15","author":"Quaglino","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib120","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/j.1529-8019.2010.01370.x","article-title":"Electrochemotherapy for cutaneous and subcutaneous tumor lesions: a novel therapeutic approach","volume":"23","author":"Testori","year":"2010","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.ejso.2016.10.005_bib121","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejcsup.2006.08.003","article-title":"Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes","volume":"4","author":"Mir","year":"2006","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ejso.2016.10.005_bib122","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1586\/14737140.6.5.671","article-title":"Role of electrochemotherapy in the treatment of metastatic melanoma and other metastatic and primary skin tumors","volume":"6","author":"Byrne","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejso.2016.10.005_bib123","first-page":"3","article-title":"Treatment of metastatic melanoma with electrochemotherapy","volume":"75","author":"Campana","year":"2014","journal-title":"J\u00a0Dermatol Sci"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib124","article-title":"Electrochemotherapy for treatment of locally advanced superficial cancer: results from a single institution","volume":"20","author":"Pennacchioli","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"10.1016\/j.ejso.2016.10.005_bib125","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CCO.0b013e32834fcaa8","article-title":"Utility of electrochemotherapy in melanoma treatment","volume":"24","author":"Testori","year":"2012","journal-title":"Curr Opin Oncol"},{"issue":"11","key":"10.1016\/j.ejso.2016.10.005_bib126","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ejcsup.2006.08.002","article-title":"Electrochemotherapy \u2013 an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study","volume":"4","author":"Marty","year":"2006","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejso.2016.10.005_bib127","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/j.ejso.2016.06.399","article-title":"Treatment efficacy with electrochemotherapy: A multi-institutional prospective observational study\u00a0on 376 patients with superficial tumors","volume":"42","author":"Campana","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib128","article-title":"Bleomycin-Based Electrochemotherapy: Clinical Outcome from a Single Institution's Experience with 52 Patients","author":"Campana","year":"2008","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib129","doi-asserted-by":"crossref","DOI":"10.1002\/bjs.8749","article-title":"Electrochemotherapy for disseminated superficial metastasesfrom malignant melanoma","author":"Campana","year":"2012","journal-title":"BJS"},{"key":"10.1016\/j.ejso.2016.10.005_bib130","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1007\/s00262-008-0462-0","article-title":"Tumour destruction using electrochemotherapy followed by CpG oligodeoxynucleotide injection induces distant tumour responses","volume":"57","author":"Roux","year":"2008","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ejso.2016.10.005_bib131","doi-asserted-by":"crossref","first-page":"e59557","DOI":"10.1371\/journal.pone.0059557","article-title":"Differential Mechanisms Associated with Vascular Disrupting Action of Electrochemotherapy: intravital microscopy on the Level of Single Normal and Tumor Blood Vessels","volume":"8","author":"Markelc","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib132","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10585-012-9505-1","article-title":"Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy","volume":"30","author":"Gerlini","year":"2013","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.ejso.2016.10.005_bib133","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/hum.2005.16.35","article-title":"Intratumoral injection of DNA encoding human interleukin 12 into patients with metastatic melanoma: clinical efficacy","volume":"16","author":"Heinzerling","year":"2005","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ejso.2016.10.005_bib134","article-title":"Systemic antitumor effect and clinical response in a phase 2 trial of intratumoral electroporation of plasmid interleukin-12 in patients with advanced melanoma","author":"Daud","year":"2014","journal-title":"ASCO"},{"issue":"6","key":"10.1016\/j.ejso.2016.10.005_bib135","doi-asserted-by":"crossref","first-page":"e1008842","DOI":"10.1080\/2162402X.2015.1008842","article-title":"Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy","volume":"4","author":"Mozzillo","year":"2015","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ejso.2016.10.005_bib136","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semradonc.2014.07.004","article-title":"Combination of radiotherapy and immune checkpoint inhibitors","volume":"25","author":"Pilones","year":"2015","journal-title":"Semin Radiol Oncol"},{"key":"10.1016\/j.ejso.2016.10.005_bib137","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.67.1529","article-title":"Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma","author":"Puzanov","year":"2016","journal-title":"JCO"}],"container-title":["European Journal of Surgical Oncology (EJSO)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316309416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798316309416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T17:26:10Z","timestamp":1657560370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798316309416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":137,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["S0748798316309416"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2016.10.005","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and treatment of in-transit melanoma metastases","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology (EJSO)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.","name":"copyright","label":"Copyright"}]}}